On July 19, Gelun Hui reported that its subsidiary, Changxing Pharmaceutical Co., Ltd., received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for oral solution of Levetiracetam. The oral solution is mainly used as an adjunctive treatment for partial seizures in adult, pediatric and infants over one month old with epilepsy.
华海药业(600521.SH)：左乙拉西坦口服溶液获得药品注册证书
Zhejiang Huahai Pharmaceutical (600521.SH): Registration certificate obtained for pharmaceutical oral solution of levetiracetam.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.